IBRX vs WAT · rev $113.3M vs P/E 32, rev $1.65B
Immunitybio Inc (IBRX) versus Waters Corporation (WAT) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Waters Corporation (WAT) is a diagnostics & research company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported WAT revenue for 2026-07-04 was $1.65B. Net income was -$136.0M. Revenue was up 29.8% from 2026-04-04 to 2026-07-04. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
IBRX currently screens at market cap $7.88B. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
Not investment advice. Open the IBRX and WAT stock pages for the full models.
Not investment advice.